世界の慢性閉塞性肺疾患（COPD）治療薬市場2022年－2031年：薬効分類別（併用療法、気管支拡張剤、副腎皮質ホルモン剤、ホスホジエステラーゼ4型阻害剤、ムコキネティクス、その他）

• 英文タイトル：Chronic Obstructive Pulmonary Disease [COPD] Treatment Market (Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

• レポートコード：TMRGL73763 • 出版社/出版日：Transparency Market Research / 2022年10月26日 • レポート形態：英文、PDF、241ページ • 納品方法：Eメール • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥857,660 (USD5,795)	▷ お問い合わせ
Multi User	￥1,301,660 (USD8,795)	▷ お問い合わせ
Corporate License	￥1,745,660 (USD11,795)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

※当レポートは英文です。下記の日本語概要・目次は自動翻訳を利用し作成されました。正確な概要・目次はお問い合わせフォームからサンプルを請求してご確認ください。

慢性閉塞性肺疾患（COPD）治療薬の世界市場紹介

慢性閉塞性肺疾患は、肺に影響を与え、呼吸困難を引き起こす疾患群です。慢性気管支炎と肺気腫は、慢性閉塞性肺疾患の2つの主要なタイプです。息苦しさは、COPDの主な特徴です。肺気腫の場合、肺の中の肺胞（小さな空気の袋）が損傷しています。肺胞の壁が引き伸ばされ、肺が大きくなり、空気の移動が困難になります。慢性気管支炎は、肺の中の気管支（呼吸する管）に炎症が起こります。世界的にCOPDの有病率が高く、COPD治療薬のパイプラインが豊富であることが、予測期間中の世界市場の牽引役と考えられます。さらに、老年人口の増加や様々な年齢層における不健康なライフスタイルの選択が、近い将来、慢性閉塞性肺疾患（COPD）治療市場を推進すると予測されます。

世界的なCOPDの有病率の上昇

慢性閉塞性肺疾患（COPD）は、世界中の多くの人々に影響を及ぼす主要な健康上の懸念事項です。疾病負担は増加しており、それによってCOPD管理の必要性が高まっています。タバコの喫煙はCOPDにつながる可能性があります。喫煙習慣のある成人の数は、世界中で増加傾向にあります。その他の危険因子としては、職業や室内空気汚染などがあります。WHOによると、COPDの主な原因はタバコの煙への暴露（能動喫煙、受動喫煙のいずれか）であるとされています。同機関によると、慢性閉塞性肺疾患（COPD）は世界第3位の死因であり、2019年の死亡者数は323万人を占めます。70歳未満のCOPDによる死亡の90％近くは、低・中所得国（LMIC）で発生しています。2022年に発表されたGlobal Initiative for Chronic Obstructive Lung Disease（GOLD）の報告によると、COPDの危険因子にさらされ続けること、間質性肺疾患の発生率の上昇、世界中の高齢化などにより、近い将来、COPDの有病率と負担は増加すると予測されています。これにより、近い将来、慢性閉塞性肺疾患治療薬の市場が拡大すると予想されます。

より効果的な併用療法の採用がCOPD治療薬の世界市場を牽引

併用療法には、LAMA-ICS、LABA-ICS、3剤併用療法、その他の併用薬が含まれます。気管支拡張剤と副腎皮質ホルモンを別々に使用するよりも効果的なため、併用療法の採用が進んでいる。気管支拡張剤や副腎皮質ホルモンの治療では回復の兆しが見られなかった患者が、併用療法によって治療に成功するケースが増加しており、世界の慢性閉塞性肺疾患治療市場の活性化につながると期待されています。併用療法は、単剤療法よりも症状やQOL（生活の質）の改善に有効です。

COPD治療の成功率の向上が、併用療法分野を強化する

COPD治療薬の世界市場は、薬剤の種類によって、併用療法、気管支拡張剤、コルチコステロイド、ホスホジエステラーゼ4型阻害剤、ムコキネティクス、その他に分類されます。2021年の世界市場では、併用療法分野が約50％の主要シェアを占めています。COPD治療における併用療法の有効性が高まっていることから、予測期間中、世界市場を支配する可能性が高いと考えられます。COPD治療における併用療法の成功率の上昇と最近の規制当局による承認は、併用療法の採用を増大させています。これにより、予測期間中、同領域が牽引されると予測されます。

喫煙者の気流障害と呼吸困難の急増が慢性気管支炎セグメントを活性化

COPD治療薬の世界市場は、タイプ別に慢性気管支炎と肺気腫に二分されます。2021年の慢性閉塞性肺疾患治療市場シェアは、慢性気管支炎セグメントが最大となりました。慢性気管支炎は、気流の閉塞と呼吸障害を引き起こす肺疾患群で、喫煙者の間で広く普及しており、急速なペースで増加しています。

COPD治療薬の調剤数の増加が小売薬局のセグメントを押し上げる

世界市場は、販売チャネル別に病院薬局、小売薬局、オンライン薬局に分類されます。小売薬局分野は、予測期間中に慢性閉塞性肺疾患治療薬の世界市場で大きなシェアを占めると予想されます。小売薬局でのCOPD治療薬調剤数の増加や、発展途上国における小売薬局の増加により、予測期間中に急成長が見込まれています。

慢性閉塞性肺疾患（COPD）治療薬市場の地域別概況

慢性閉塞性肺疾患治療薬市場の分析によると、2021年の世界市場のうち、北米が約40％の最大シェアを占めています。同地域の市場は、2022年から2031年にかけてCAGR4.3％で成長すると予測されています。これは、高度に構造化された医療業界と、民間および公的医療保険会社による明確な償還政策が利用可能であることに起因していると思われます。さらに、高度で効率的な製品を提供するための研究開発活動の増加、および多数のプレイヤーの存在が、北米の慢性閉塞性肺疾患治療市場規模を押し上げています。
欧州は、2021年の世界市場で2番目に大きなシェアを占めています。整備された医療インフラと慢性閉塞性肺疾患の罹患率の増加が、同地域のCOPD治療市場を促進しています。
アジア太平洋地域の市場は、予測期間中に最も速いCAGR 4.7%で成長すると予測されます。同地域は、先進地域と比較して慢性閉塞性肺疾患治療市場が比較的未開拓であることが特徴です。そのため、アジア太平洋地域は市場関係者に大きな機会を提供しています。慢性閉塞性肺疾患の高い有病率、老人人口の増加、患者数の急増、医療産業の成長が、同地域の慢性閉塞性肺疾患治療市場を促進しています。

レポート目次

---

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlight

2. Assumptions and Research Methodology

3. Executive Summary: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

4. Market Overview

4.1. Introduction

4.1.1. Segment Definition

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, 2017–2031

4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Regulatory Scenario by Region/globally

5.2. Reimbursement Scenario by Region/globally

5.3. Pipeline Analysis

5.4. Technological Advancements

5.5. Pricing Analysis (Brand pricing, Average Selling Price by Region/Country)

5.6. Disease Prevalence & Incidence Rate globally with key countries

5.7. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)

5.8. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast, by Drug Class, 2017–2031

6.3.1. Combination Therapy

6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

6.3.1.3. Triple therapy

6.3.1.4. Others

6.3.2. Bronchodilators

6.3.2.1. Long Acting Beta Agonist (LABA)

6.3.2.2. Short Acting Beta Agonist (SABA)

6.3.2.3. Long Acting Muscarinic Antagonist (LAMA)

6.3.3. Corticosteroids

6.3.4. Phosphodiesterase Type 4 Inhibitor

6.3.5. Mucokinetics

6.3.6. Others

6.4. Market Attractiveness Analysis, by Drug Class

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Type

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast, by Type, 2017–2031

7.3.1. Chronic Bronchitis

7.3.2. Emphysema

7.4. Market Attractiveness Analysis, by Type

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Distribution Channel

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Market Value Forecast, by Distribution Channel, 2017–2031

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Online Pharmacies

8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Region

9.1. Key Findings

9.2. Market Value Forecast, by Region

9.2.1. North America

9.2.2. Europe

9.2.3. Asia Pacific

9.2.4. Latin America

9.2.5. Middle East & Africa

9.3. Market Attractiveness Analysis, by Region

10. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. Market Value Forecast, by Drug Class, 2017–2031

10.2.1. Combination Therapy

10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

10.2.1.3. Triple therapy

10.2.1.4. Others

10.2.2. Bronchodilators

10.2.2.1. Long Acting Beta Agonist (LABA)

10.2.2.2. Short Acting Beta Agonist (SABA)

10.2.2.3. Long Acting Muscarinic Antagonist (LAMA)

10.2.3. Corticosteroids

10.2.4. Phosphodiesterase Type 4 Inhibitor

10.2.5. Mucokinetics

10.2.6. Others

10.3. Market Value Forecast, by Type, 2017–2031

10.3.1. Chronic Bronchitis

10.3.2. Emphysema

10.4. Market Value Forecast, by Distribution Channel, 2017–2031

10.4.1. Hospital Pharmacies

10.4.2. Retail Pharmacies

10.4.3. Online Pharmacies

10.5. Market Value Forecast, by Country, 2017–2031

10.5.1. U.S.

10.5.2. Canada

10.6. Market Attractiveness Analysis

10.6.1. By Drug Class

10.6.2. By Type

10.6.3. By Distribution Channel

10.6.4. By Country

11. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Market Value Forecast, by Drug Class, 2017–2031

11.2.1. Combination Therapy

11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

11.2.1.3. Triple therapy

11.2.1.4. Others

11.2.2. Bronchodilators

11.2.2.1. Long Acting Beta Agonist (LABA)

11.2.2.2. Short Acting Beta Agonist (SABA)

11.2.2.3. Long Acting Muscarinic Antagonist (LAMA)

11.2.3. Corticosteroids

11.2.4. Phosphodiesterase Type 4 Inhibitor

11.2.5. Mucokinetics

11.2.6. Others

11.3. Market Value Forecast, by Type, 2017–2031

11.3.1. Chronic Bronchitis

11.3.2. Emphysema

11.4. Market Value Forecast, by Distribution Channel, 2017–2031

11.4.1. Hospital Pharmacies

11.4.2. Retail Pharmacies

11.4.3. Online Pharmacies

11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

11.5.1. Germany

11.5.2. U.K.

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Rest of Europe

11.6. Market Attractiveness Analysis

11.6.1. By Drug Class

11.6.2. By Type

11.6.3. By Distribution Channel

11.6.4. By Country/Sub-region

12. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Market Value Forecast, by Drug Class, 2017–2031

12.2.1. Combination Therapy

12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

12.2.1.3. Triple therapy

12.2.1.4. Others

12.2.2. Bronchodilators

12.2.2.1. Long Acting Beta Agonist (LABA)

12.2.2.2. Short Acting Beta Agonist (SABA)

12.2.2.3. Long Acting Muscarinic Antagonist (LAMA)

12.2.3. Corticosteroids

12.2.4. Phosphodiesterase Type 4 Inhibitor

12.2.5. Mucokinetics

12.2.6. Others

12.3. Market Value Forecast, by Type, 2017–2031

12.3.1. Chronic Bronchitis

12.3.2. Emphysema

12.4. Market Value Forecast, by Distribution Channel, 2017–2031

12.4.1. Hospital Pharmacies

12.4.2. Retail Pharmacies

12.4.3. Online Pharmacies

12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

12.5.1. China

12.5.2. Japan

12.5.3. India

12.5.4. Australia & New Zealand

12.5.5. Rest of Asia Pacific

12.6. Market Attractiveness Analysis

12.6.1. By Drug Class

12.6.2. By Type

12.6.3. By Distribution Channel

12.6.4. By Country/Sub-region

13. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Market Value Forecast, by Drug Class, 2017–2031

13.2.1. Combination Therapy

13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

13.2.1.3. Triple therapy

13.2.1.4. Others

13.2.2. Bronchodilators

13.2.2.1. Long Acting Beta Agonist (LABA)

13.2.2.2. Short Acting Beta Agonist (SABA)

13.2.2.3. Long Acting Muscarinic Antagonist (LAMA)

13.2.3. Corticosteroids

13.2.4. Phosphodiesterase Type 4 Inhibitor

13.2.5. Mucokinetics

13.2.6. Others

13.3. Market Value Forecast, by Type, 2017–2031

13.3.1. Chronic Bronchitis

13.3.2. Emphysema

13.4. Market Value Forecast, by Distribution Channel, 2017–2031

13.4.1. Hospital Pharmacies

13.4.2. Retail Pharmacies

13.4.3. Online Pharmacies

13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

13.5.1. Brazil

13.5.2. Mexico

13.5.3. Rest of Latin America

13.6. Market Attractiveness Analysis

13.6.1. By Drug Class

13.6.2. By Type

13.6.3. By Distribution Channel

13.6.4. By Country/Sub-region

14. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

14.1. Introduction

14.1.1. Key Findings

14.2. Market Value Forecast, by Drug Class, 2017–2031

14.2.1. Combination Therapy

14.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

14.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

14.2.1.3. Triple therapy

14.2.1.4. Others

14.2.2. Bronchodilators

14.2.2.1. Long Acting Beta Agonist (LABA)

14.2.2.2. Short Acting Beta Agonist (SABA)

14.2.2.3. Long Acting Muscarinic Antagonist (LAMA)

14.2.3. Corticosteroids

14.2.4. Phosphodiesterase Type 4 Inhibitor

14.2.5. Mucokinetics

14.2.6. Others

14.3. Market Value Forecast, by Type, 2017–2031

14.3.1. Chronic Bronchitis

14.3.2. Emphysema

14.4. Market Value Forecast, by Distribution Channel, 2017–2031

14.4.1. Hospital Pharmacies

14.4.2. Retail Pharmacies

14.4.3. Online Pharmacies

14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

14.5.1. GCC Countries

14.5.2. South Africa

14.5.3. Rest of Middle East & Africa

14.6. Market Attractiveness Analysis

14.6.1. By Drug Class

14.6.2. By Type

14.6.3. By Distribution Channel

14.6.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Player – Competition Matrix (by tier and size of companies)

15.2. Market Share Analysis, by Company, 2021

15.3. Company Profiles

15.3.1. F. Hoffmann-La Roche Ltd.

15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.1.2. Product Portfolio

15.3.1.3. Financial Overview

15.3.1.4. SWOT Analysis

15.3.1.5. Strategic Overview

15.3.2. AstraZeneca

15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.2.2. Product Portfolio

15.3.2.3. Financial Overview

15.3.2.4. SWOT Analysis

15.3.2.5. Strategic Overview

15.3.3. GlaxoSmithKline plc

15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.3.2. Product Portfolio

15.3.3.3. Financial Overview

15.3.3.4. SWOT Analysis

15.3.3.5. Strategic Overview

15.3.4. Sanofi

15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.4.2. Product Portfolio

15.3.4.3. Financial Overview

15.3.4.4. SWOT Analysis

15.3.4.5. Strategic Overview

15.3.5. Novartis AG

15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.5.2. Product Portfolio

15.3.5.3. Financial Overview

15.3.5.4. SWOT Analysis

15.3.5.5. Strategic Overview

15.3.6. Teva Pharmaceutical Industries Ltd.

15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.6.2. Product Portfolio

15.3.6.3. Financial Overview

15.3.6.4. SWOT Analysis

15.3.6.5. Strategic Overview

15.3.7. Mylan N.V.

15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.7.2. Product Portfolio

15.3.7.3. Financial Overview

15.3.7.4. SWOT Analysis

15.3.7.5. Strategic Overview

15.3.8. Boehringer Ingelheim International GmbH

15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.8.2. Product Portfolio

15.3.8.3. Financial Overview

15.3.8.4. SWOT Analysis

15.3.8.5. Strategic Overview

15.3.9. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)

15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.9.2. Product Portfolio

15.3.9.3. Financial Overview

15.3.9.4. SWOT Analysis

15.3.9.5. Strategic Overview

15.3.10. CHIESI Farmaceutici S.p.A.

15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.10.2. Product Portfolio

15.3.10.3. Financial Overview

15.3.10.4. SWOT Analysis

15.3.10.5. Strategic Overview

15.3.11. Orion Corporation

15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.11.2. Product Portfolio

15.3.11.3. Financial Overview

15.3.11.4. SWOT Analysis

15.3.11.5. Strategic Overview

15.3.12. Almirall

15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.12.2. Product Portfolio

15.3.12.3. Financial Overview

15.3.12.4. SWOT Analysis

15.3.12.5. Strategic Overview

15.3.13. Theravance Biopharma

15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.13.2. Product Portfolio

15.3.13.3. Financial Overview

15.3.13.4. SWOT Analysis

15.3.13.5. Strategic Overview

15.3.14. Verona Pharmaceuticals

15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.14.2. Product Portfolio

15.3.14.3. Financial Overview

15.3.14.4. SWOT Analysis

15.3.14.5. Strategic Overview

15.3.15. Kyowa Hakko Kirin

15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.15.2. Product Portfolio

15.3.15.3. Financial Overview

15.3.15.4. SWOT Analysis

15.3.15.5. Strategic Overview

List of Tables

Table 01: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 02: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by 2017‒2031, by Combination Therapy

Table 03: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by 2017‒2031, by Bronchodilators

Table 04: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 05: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 06: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 07: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 08: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 09: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031

Table 10: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031

Table 11: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 12: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 15: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031

Table 16: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031

Table 17: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 18: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 19: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 20: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 21: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031

Table 22: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031

Table 23: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 24: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 25: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 26: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 27: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031

Table 28: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031

Table 29: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 30: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 31: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 32: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 33: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031

Table 34: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031

Table 35: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 36: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

---